Business Acquisition, Contingent Consideration, Per Share

No definition available.

Name:	asrt_BusinessAcquisitionContingentConsiderationPerShare
Namespace Prefix:	asrt_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Business Acquisition, Contingent Consideration, Per Share, Maximum

+ References

No definition available.

+ Details

Name:	asrt_BusinessAcquisitionContingentConsiderationPerShareMaximum
Namespace Prefix:	asrt_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Business Acquisition, Fixed Exchange Ratio

+ References

No definition available.

+ Details

Name:	asrt_BusinessAcquisitionFixedExchangeRatio
Namespace Prefix:	asrt_
Data Type:	dtr-types1:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Business Combination, Contingent Consideration Liability, Number of Shares

+ References

No definition available.

+ Details

Name:	asrt_BusinessCombinationContingentConsiderationLiabilityNumberOfShares
Namespace Prefix:	asrt_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482665/350-30-50-1

+ Details

Name:	us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479907/805-20-50-5

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 25
-Paragraph 23
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479405/805-10-25-23

+ Details

Name:	us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479581/805-30-50-1

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	us-gaap_BusinessAcquisitionAxis=asrt_SpectrumPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=asrt_RolvedonMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

ACQUISITIONS - Narrative (Details) - Spectrum Pharmaceuticals, Inc. - USD ($) $ / shares in Units, $ in Millions		3 Months Ended	9 Months Ended
	Jul. 31, 2023	Sep. 30, 2023	Sep. 30, 2023	Dec. 31, 2025	Dec. 31, 2024
Business Acquisition [Line Items]
Business acquisition, fixed exchange ratio	$ 0.1783
Business acquisition, contingent consideration, per share, maximum (in dollars per share)	$ 0.20
Business combination, contingent consideration liability, number of shares (in shares)	223,397
Business acquisition, contingent consideration, per share (in dollars per share)	$ 0.0176
Acquired finite-lived intangible assets, useful life	10 years
Acquisition costs related to the transaction		$ 2.7	$ 8.5
ROLVEDON
Business Acquisition [Line Items]
Business combination, contingent consideration arrangements, range of outcomes, value, high	$ 44.7
ROLVEDON \| Forecast
Business Acquisition [Line Items]
Business acquisition, contingent consideration, per share, maximum (in dollars per share)				$ 0.10	$ 0.10
Business combination, contingent consideration arrangements, range of outcomes, value, high				$ 225.0	$ 175.0